


NiCCC


Nintedanib in Clear Cell Carcinoma

A Randomised Phase II Study of BIBF 1120 versus
Chemotherapy in Recurrent Clear Cell Carcinoma of the
Ovary or Endometrium

SGCTG/NCRI/NSGO



NiCCC Trial Design



Primary Endpoint: PFS

Secondary Endpoints: OS, Toxicity, RR, QoL, Q-Twist

Trial Status

- Study opened in the UK April 2015
 - First 2 centres have opened
 - 1st patient randomised April 2015
- GINECO, EORTC and NSGO in set up